<DOC>
	<DOCNO>NCT00044083</DOCNO>
	<brief_summary>This study evaluate whether Tolcapone improve cognition healthy volunteer well patient schizophrenia . Talcapone drug FDA approve Attention Deficit Disorder allegedly increase amount neurotransmitter dopamine frontal cortex brain .</brief_summary>
	<brief_title>Clinical Trial Tolcapone Cognition Schizophrenia</brief_title>
	<detailed_description>Psychopharmacological modulation catecholaminergic system enhance aspect cognitive function . For example , COMT inhibitor slightly improve work memory/executive function . Differences response individual might relate number factor , include variation gene . The recent finding polymorphism catechol-o-methyl-transferase ( COMT ) gene , produce 4 fold change enzyme activity , account 4 percent variance performance work memory task human suggest COMT genotype may predict response COMT inhibitor . In present investigation goal examine , normal control patient schizophrenia , effect centrally act ( tolcapone ) peripherally act ( entacapone ) COMT inhibitor cognitive function . We predict normal control patient schizophrenia val/val genotype significant , though transient , improvement work memory subject treat tolcapone treat entacapone . Furthermore , conjunction NIMH imaging protocol , would like examine neurophysiological correlate related working memory . We predict , tolcapone treat subject , improve measure prefrontal 'efficiency ' subject patient specifically val/val genotype . The present protocol provide new insight importance genetic polymorphism regulation aminergic-controlled cognitive function normal individual . Furthermore , protocol test whether COMT inhibitor offer new treatment-based genotype - cognitive impairment schizophrenia . No IND require present study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Tolcapone</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Prior participation NIH protocol number 95M0150 , new normal volunteer schizophrenic patient meet criterion NIH protocol number 95M0150 . 2 . No Axis I Axis II diagnosis normal volunteer . 3 . Age range : 1850 year . EXCLUSION CRITERIA : 1 . Normal volunteer Axis I Axis II disorder obtain either prior SCID interview Protocol 95M0150 screen interview exclude . 2 . Subjects history cardiovascular disease , liver disease medical illness , untreated uncontrolled hypertension exclude . An electrocardiogram , blood pressure , pulse rate metabolic panel include LFTs check subject prior participation study . Individuals persistent tardive dyskinesia abnormal LFTs , individual significant history alcoholism liver enzyme elevation exclude study . 3 . Schizophrenic patient take clozapine , COMT inhibitor , illicit drug abuse , MAO inhibitor exclude . 4 . Normal control subject take medication occasional NSAI exclude . 5 . Pregnant woman . Women childbearing potential undergo urine pregnancy test day study initiate screen history possibility pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Catecholamines</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>fMRI</keyword>
	<keyword>PFC</keyword>
	<keyword>Vitamin B2</keyword>
	<keyword>Riboflavin</keyword>
	<keyword>Tolcapone</keyword>
	<keyword>Placebo</keyword>
	<keyword>Normal Volunteers</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>HV</keyword>
</DOC>